IP Library Granted Patent US 10,682,379
Granted Patent B2
US 10,682,379 · App. 16/249,721 · Granted Jun 16, 2020

Use of gram negative species to treat atopic dermatitis

Inventors: Ian Antheni Myles (Bethesda, MD); Sandip K. Datta (Bethesda, MD)
Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
A61K35/74A61K9/0014A61K9/06A61P17/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,682,379
App. No.
16/249,721
Granted
Jun 16, 2020
Kind
B2
Abstract

Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

Claims (17)

1. A method for culturing gram negative bacteria from skin, comprising:

depositing a sample from skin of a subject in a liquid culture medium, wherein the liquid culture medium comprises a low nutrient medium containing essential nutrients for bacterial growth, an anti-gram positive bacterial agent, and an antifungal agent; and

liquid culturing the sample in the liquid culture medium under conditions to inhibit growth of gram positive bacteria and fungi, thereby generating a population of cultured bacteria from the sample comprising at least one species of gram negative bacteria.

2. The method of claim 1 , wherein the sample is from antecubital fossa of the skin of the subject.

3. The method of claim 1 , wherein the subject does not have atopic dermatitis.

4. The method of claim 1 , wherein the sample comprises gram negative bacteria and gram positive bacteria.

5. The method of claim 1 , wherein the liquid culturing is followed by solid culturing on a plate.

6. The method of claim 1 , wherein the at least one species of gram negative bacteria comprises Acinetobacter radioresistens, Moraxella osloensis, Pantoea septica, Pseudomonas luteola, Pseudomonas aeruginosa , or Pseudomonas oryzihabitans.

7. The method of claim 1 , wherein the at least one species of gram negative bacteria comprises Roseomonas mucosa.

8. The method of claim 1 , wherein the low nutrient medium is selected from the group consisting of Hank's balanced salt solution and Reasoner's 2A medium.

9. The method of claim 1 , wherein the anti-gram positive bacterial agent is vancomycin.

10. The method of claim 1 , wherein the antifungal agent is amphotericin B.

11. The method of claim 1 , wherein the anti-gram positive bacterial agent is vancomycin, wherein the antifungal agent is amphotericin B, and wherein the low nutrient medium is selected from the group consisting of Hank's balanced salt solution and Reasoner's 2A media medium.

12. The method of claim 11 , wherein the at least one species of gram negative bacteria comprises Acinetobacter radioresistens, Moraxella osloensis, Pantoea septica, Pseudomonas luteola, Pseudomonas aeruginosa , or Pseudomonas oryzihabitans.

13. The method of claim 11 , wherein the at least one species of gram negative bacteria comprises Roseomonas mucosa.

14. The method of claim 1 , wherein the subject is a human.

15. The method of claim 5 , wherein the plate is an agar plate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: MYLES, IAN ANTHENI; DATTA, SANDIP K.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 048617/0071 →
Continuity (5)
Continuation 16014971 · Jun 21, 2018
Division 15939066 · Mar 28, 2018
Continuation PCTUS2017028133 · Apr 18, 2017
Provisional Application 62324762 · Apr 19, 2016
Related Publication 20190142874A1 · May 16, 2019